Royal Fund Management LLC Buys 19,137 Shares of SPDR S&P Biotech ETF $XBI

Royal Fund Management LLC grew its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 13.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 162,850 shares of the exchange traded fund’s stock after buying an additional 19,137 shares during the quarter. SPDR S&P Biotech ETF accounts for approximately 2.0% of Royal Fund Management LLC’s portfolio, making the stock its 5th biggest position. Royal Fund Management LLC owned approximately 0.26% of SPDR S&P Biotech ETF worth $20,814,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of XBI. Compound Planning Inc. raised its holdings in SPDR S&P Biotech ETF by 0.7% during the first quarter. Compound Planning Inc. now owns 10,889 shares of the exchange traded fund’s stock worth $1,391,000 after purchasing an additional 75 shares in the last quarter. Dynamic Wealth Strategies LLC lifted its stake in SPDR S&P Biotech ETF by 3.8% in the fourth quarter. Dynamic Wealth Strategies LLC now owns 2,201 shares of the exchange traded fund’s stock valued at $268,000 after buying an additional 80 shares during the last quarter. Capital Investment Advisory Services LLC lifted its stake in SPDR S&P Biotech ETF by 4.0% in the fourth quarter. Capital Investment Advisory Services LLC now owns 2,123 shares of the exchange traded fund’s stock valued at $259,000 after buying an additional 81 shares during the last quarter. PeakShares LLC boosted its holdings in shares of SPDR S&P Biotech ETF by 5.2% in the first quarter. PeakShares LLC now owns 1,684 shares of the exchange traded fund’s stock valued at $215,000 after acquiring an additional 84 shares during the period. Finally, Commerce Bank boosted its holdings in shares of SPDR S&P Biotech ETF by 2.8% in the fourth quarter. Commerce Bank now owns 3,260 shares of the exchange traded fund’s stock valued at $397,000 after acquiring an additional 90 shares during the period.

SPDR S&P Biotech ETF Trading Down 1.2%

Shares of XBI opened at $147.91 on Thursday. The company’s 50 day simple moving average is $145.48 and its 200-day simple moving average is $134.07. The firm has a market cap of $9.73 billion, a PE ratio of 11.47 and a beta of 0.82. SPDR S&P Biotech ETF has a 12-month low of $84.39 and a 12-month high of $165.71.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.